Should You Buy Visa Stock Now?
Having operations across 200 countries, Visa Inc. (NYSE:V) is arguably…
Sell
43
AVTX Quote, Financials, Valuation and Earnings
Last price:
$4.30
Seasonality move
:
-0.66%
Day range:
$4.13 - $4.55
52-week range:
$3.39 - $16.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.30x
P/B ratio:
0.38x
Volume:
49.7K
Avg. volume:
60K
1-year change:
-60.45%
Market cap:
$47.1M
Revenue:
$441K
EPS (TTM):
-$3,384.24
Analysts' Opinion
-
Consensus RatingAvalo Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.88, Avalo Therapeutics has an estimated upside of 586.78% from its current price of $4.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -244.83% downside risk from its current price of $4.35.
Fair Value
-
According to the consensus of 6 analysts, Avalo Therapeutics has 586.78% upside to fair value with a price target of $29.88 per share.
AVTX vs. S&P 500
-
Over the past 5 trading days, Avalo Therapeutics has overperformed the S&P 500 by 19.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Avalo Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avalo Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avalo Therapeutics reported revenues of $192K.
Earnings Growth
-
Avalo Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Avalo Therapeutics reported earnings per share of -$1.25.
Enterprise value:
-77.9M
EV / Invested capital:
--
Price / LTM sales:
1.30x
EV / EBIT:
--
EV / Revenue:
-0.06x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$725K
Return On Assets:
-34.97%
Net Income Margin (TTM):
-1638.65%
Return On Equity:
-375.96%
Return On Invested Capital:
-375.96%
Operating Margin:
-6932.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $17.4M | -- | -- | -- | -- | |
| Gross Profit | $14.1M | $796K | $725K | $80K | -- | |
| Operating Income | -$25.4M | -$47.4M | -$50.4M | -$32.8M | -$14.7M | |
| EBITDA | -$25.2M | -$47.3M | -$50.1M | -$32.7M | -$14.5M | |
| Diluted EPS | -$703.00 | -$318.89 | -$3,384.24 | -$141.14 | -$1.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $46.1M | $43.7M | $19.3M | $111.2M | $126.9M | |
| Total Assets | $63.3M | $61.9M | $36.2M | $123.7M | $138.5M | |
| Current Liabilities | $26.4M | $17.9M | $23.2M | $215.7M | $5.6M | |
| Total Liabilities | $30.2M | $55.6M | $42.5M | $224.8M | $15.9M | |
| Total Equity | $33.2M | $6.3M | -$6.3M | -$101.1M | $122.6M | |
| Total Debt | -- | $33.2M | $19.8M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.7M | -$26.8M | -$52.3M | -$6.2M | -$9.5M | |
| Cash From Investing | -$228K | $356K | -- | $356K | -- | |
| Cash From Financing | -$951K | $119.9M | $67.2M | $108.6M | -- | |
| Free Cash Flow | -$20.7M | -$26.8M | -$52.3M | -$6.2M | -$9.5M | |
AVTX
Sector
Market Cap
$47.1M
$33.6M
Price % of 52-Week High
27.19%
45.68%
Dividend Yield
0%
0%
Shareholder Yield
-148.61%
-0.66%
1-Year Price Total Return
-60.46%
-38.85%
Beta (5-Year)
0.696
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.97
200-day SMA
Sell
Level
$8.13
Bollinger Bands (100)
Sell
Level
4.65 - 7.85
Chaikin Money Flow
Sell
Level
-23.8M
20-day SMA
Buy
Level
$3.97
Relative Strength Index (RSI14)
Buy
Level
50.53
ADX Line
Buy
Level
13.08
Williams %R
Neutral
Level
-28.1536
50-day SMA
Sell
Level
$5.04
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
33.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2482)
Sell
CA Score
(Annual)
Level (-2.6046)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.3978)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Stock Forecast FAQ
In the current month, AVTX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AVTX average analyst price target in the past 3 months is $29.88.
-
Where Will Avalo Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avalo Therapeutics share price will rise to $29.88 per share over the next 12 months.
-
What Do Analysts Say About Avalo Therapeutics?
Analysts are divided on their view about Avalo Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avalo Therapeutics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Avalo Therapeutics's Price Target?
The price target for Avalo Therapeutics over the next 1-year time period is forecast to be $29.88 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AVTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avalo Therapeutics is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVTX?
You can purchase shares of Avalo Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avalo Therapeutics shares.
-
What Is The Avalo Therapeutics Share Price Today?
Avalo Therapeutics was last trading at $4.30 per share. This represents the most recent stock quote for Avalo Therapeutics. Yesterday, Avalo Therapeutics closed at $4.35 per share.
-
How To Buy Avalo Therapeutics Stock Online?
In order to purchase Avalo Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Trillion-Dollar Stock?
Shares of AI and data analytics leader Palantir (NASDAQ:PLTR) have…
Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
SBET alert for Jun 5
SharpLink Gaming [SBET] is down 27.96% over the past day.
Buy
80
GWRE alert for Jun 5
Guidewire Software [GWRE] is up 0.78% over the past day.
Buy
70
ZLAB alert for Jun 5
Zai Lab [ZLAB] is up 1.27% over the past day.
